恐惧症治疗市场－全球产业规模、份额、趋势、机会和预测，按恐惧症类型、治疗方法、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球恐惧症治疗市场规模为19.2亿美元，预计2030年将以5.78%的复合年增长率成长至26.9亿美元。恐惧症治疗涵盖多种旨在缓解对特定物体、情境或活动的强烈且非理性恐惧的治疗介入。这些治疗主要包括心理疗法，例如认知行为疗法和暴露疗法，并经常辅以药物疗法，包括抗焦虑药物和抗忧郁药，以控制相关症状。市场成长的主要驱动因素包括：全球对精神健康问题的认识不断提高和污名化现象的消除；对实证心理介入措施的需求日益增长；以及治疗模式的不断进步，包括基于数位和虚拟实境的解决方案。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球恐惧症治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依恐惧症类型分类（动物恐惧症、惧高症、广场恐惧症、幽闭恐惧症、社交恐惧症、其他）
  • 依治疗方法（疗法、药物）
  • 按最终使用者（医院、精神科诊所、恐惧症治疗中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美恐惧症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲恐惧症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区恐惧症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲恐惧症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美恐惧症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球恐惧症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Sanofi SA
• Cambrex Corporation
• Teva Pharmaceutical Industries Ltd
• Midas Pharma GmbH
• Harman Finochem Ltd
• Pfizer Inc.
• AstraZeneca, Plc.
• Eli Lilly and Company
• Lupin Limited
• GlaxoSmithKline plc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Phobia Treatment Market , valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 5.78% to reach USD 2.69 Billion by 2030. Phobia treatment encompasses a variety of therapeutic interventions designed to alleviate intense and irrational fears of specific objects, situations, or activities. These treatments primarily involve psychotherapy, such as cognitive-behavioral therapy and exposure therapy, frequently complemented by pharmacotherapy, including anxiolytics and antidepressants, to manage associated symptoms. The market's growth is largely supported by increasing global awareness and destigmatization of mental health conditions, a rising demand for evidence-based psychological interventions, and ongoing advancements in therapeutic modalities, including digital and virtual reality-based solutions.

Key Market Drivers

The increasing prevalence of phobia-related disorders and growing awareness of mental health are pivotal in driving the global phobia treatment market. As a subset of anxiety disorders, the widespread incidence of these conditions creates substantial demand for therapeutic interventions. According to the World Health Organization, in its September 2025 "Anxiety disorders" fact sheet, 359 million people globally were affected by anxiety disorders in 2021, signifying a pervasive need for effective treatment. This underlying requirement is actively met as growing awareness and acceptance encourage individuals to seek professional help. Proactive governmental and healthcare initiatives further bolster this shift away from stigmatization.

Key Market Challenges

The persistent limited access to specialized mental health professionals globally constitutes a significant challenge for the expansion of the phobia treatment market. Despite the high prevalence of phobias and increasing mental health awareness, a substantial portion of the affected population struggles to receive appropriate care. This access barrier directly curtails the availability and delivery of effective therapeutic interventions, such as cognitive-behavioral therapy and exposure therapy. According to the World Health Organization's Mental Health Atlas 2024, the global median for mental health workers was 13 per 100,000 people, but this figure demonstrates extreme disparities, with lower-income countries reporting as few as 1.1 specialized mental health workers per 100,000 people compared to 67.2 in high-income countries. Such a pronounced shortage of trained professionals, particularly in underserved regions, means that many individuals seeking treatment cannot initiate or sustain their care, thereby restricting the market's potential for growth and the overall reach of phobia treatment services.

Key Market Trends

The integration of Virtual Reality (VR) exposure therapy represents a transformative trend in the global phobia treatment market. This innovative approach provides immersive and controllable environments, allowing patients to safely and repeatedly confront their specific phobias, thereby overcoming the practical and logistical challenges associated with traditional in-vivo exposure. The growing clinical acceptance of this modality is evident, with the American Psychiatric Association, in its October 2023 article "Transforming Mental Health Care: The Rise of VR/AR Applications in Psychiatry," highlighting VR's broad applications in psychiatry, including its common use in immersive exposure therapy for phobias. This underscores the increasing relevance and endorsement of VR within the professional mental healthcare community.

Key Market Players

• Sanofi S.A
• Cambrex Corporation
• Teva Pharmaceutical Industries Ltd
• Midas Pharma GmbH
• Harman Finochem Ltd
• Pfizer Inc.
• AstraZeneca, Plc.
• Eli Lilly and Company
• Lupin Limited
• GlaxoSmithKline plc

Report Scope:

In this report, the Global Phobia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Phobia Treatment Market , By Type of Phobia:

• Zoophobia
• Acrophobia
• Agoraphobia
• Claustrophobia
• Social Phobia
• Others

Phobia Treatment Market , By Treatment:

• Therapy
• Medication

Phobia Treatment Market , By End User:

• Hospitals
• Psychiatry Clinics
• Phobia Treatment Centers
• Others

Phobia Treatment Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Phobia Treatment Market .

Available Customizations:

Global Phobia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Phobia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Phobia (Zoophobia, Acrophobia, Agoraphobia, Claustrophobia, Social Phobia, Others)
  • 5.2.2. By Treatment (Therapy, Medication)
  • 5.2.3. By End User (Hospitals, Psychiatry Clinics, Phobia Treatment Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Phobia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Phobia
  • 6.2.2. By Treatment
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Phobia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Phobia
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Phobia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Phobia
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Phobia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Phobia
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End User

7. Europe Phobia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Phobia
  • 7.2.2. By Treatment
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Phobia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Phobia
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End User
  • 7.3.2. France Phobia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Phobia
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Phobia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Phobia
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Phobia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Phobia
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Phobia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Phobia
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End User

8. Asia Pacific Phobia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Phobia
  • 8.2.2. By Treatment
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Phobia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Phobia
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End User
  • 8.3.2. India Phobia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Phobia
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Phobia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Phobia
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Phobia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Phobia
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Phobia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Phobia
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End User

9. Middle East & Africa Phobia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Phobia
  • 9.2.2. By Treatment
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Phobia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Phobia
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Phobia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Phobia
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Phobia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Phobia
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End User

10. South America Phobia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Phobia
  • 10.2.2. By Treatment
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Phobia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Phobia
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Phobia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Phobia
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Phobia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Phobia
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Phobia Treatment Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cambrex Corporation
• 15.3. Teva Pharmaceutical Industries Ltd
• 15.4. Midas Pharma GmbH
• 15.5. Harman Finochem Ltd
• 15.6. Pfizer Inc.
• 15.7. AstraZeneca, Plc.
• 15.8. Eli Lilly and Company
• 15.9. Lupin Limited
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer